
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial looked at a drug called panobinostat for people with Hodgkin lymphoma. It was open to people whose Hodgkin lymphoma had come back after high dose chemotherapy and a stem cell transplant, or had not responded to this treatment.
Doctors may use chemotherapy and radiotherapy to treat Hodgkin lymphoma. Some people have high dose chemotherapy followed by a stem cell transplant. Researchers are trying to find treatments that will help people who have Hodgkin lymphoma that doesn’t respond or comes back after having this type of standard treatment.
Panobinostat is a drug that blocks called deacetylases (pronounced dee-as-et-isle-azes). Cells need these enzymes to grow and divide. Blocking them may stop cancer growing.
Research in the laboratory had shown that panobinostat could stop Hodgkin lymphoma cells growing. The main aims of this trial were to
The trial team found that panobinostat could help people with Hodgkin lymphoma that had come back after a stem cell transplant.
This trial recruited 129 people. Everyone had panobinostat.
Of the 96 people whose Hodgkin lymphoma had responded
The average amount of time it took for their lymphoma to come back or get worse was just under 6 months.
The most common side effects reported were
The trial team concluded panobinostat can help people with Hodgkin lymphoma who had already had a stem cell transplant. They also found out more about the side effects of panobinostat.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists () but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor John Radford
Experimental Cancer Medicine Centre (ECMC)
Novartis
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”